Edwards Lifesciences CorporationEWNYSE
LOADING
|||
Cash Flow Under Pressure
Trending lower, below historical average, slight contraction.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$289.90M
↓ 60% below average
Average (9y)
$726.36M
Historical baseline
Range
High:$1.40B
Low:$289.90M
CAGR
-4.6%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $289.90M | -53.9% |
| 2023 | $629.50M | -34.0% |
| 2022 | $953.40M | -32.0% |
| 2021 | $1.40B | +116.7% |
| 2020 | $647.00M | -28.2% |
| 2019 | $901.00M | +31.5% |
| 2018 | $685.10M | -17.0% |
| 2017 | $825.20M | +69.4% |
| 2016 | $487.00M | +9.9% |
| 2015 | $443.20M | - |